Japan's Shionogi seeks China approval for superbug-fighting antibiotic
OSAKA -- Japanese drugmaker Shionogi announced on Monday that Chinese authorities have accepted its application filing to manufacture and sell Cefiderocol, used to treat antimicrobial-resistant infections for which existing antibiotics are ineffective.
A Chinese group company had been conducting Phase 3 clinical trials in China. After efficacy and safety were demonstrated, it applied for approval from authorities.